Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Risk evaluation & mitigation (REMS) stories

Nov 18, 2026

FDA approves Regeneron drug for generalized myasthenia gravis

The FDA approved Regeneron Pharmaceuticals' drug to treat adults with generalized myasthenia gravis, a rare autoimmune disease.

Nov 18, 2026·4 sources
00
Nov 13, 2026

FDA approves injectable nanobody gefurulimab for myasthenia gravis

The FDA granted approval to gefurulimab, a nanobody targeting the complement protein C5, for the treatment of myasthenia gravis, joining other approved C5 inhibitors in the indication.

Nov 13, 2026·2 sources
00

Top claims

  • ▪The U.S. FDA approved Regeneron Pharmaceuticals' Livsayis (cemdisiran) on November 18, 2026, for adult patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
  • ▪Livsayis is a complement component factor 5 directed small interfering RNA therapeutic that degrades C5 messenger RNA to block C5 protein production
  • ▪The FDA prescribing information for Regeneron's Livsayis includes a Boxed Warning for serious meningococcal infections and requires access through a restricted Risk Evaluation and Mitigation Strategy program

Subtopics

Clinical trials2Drug Policy, Pricing & Approval2European Union2FDA drug approval2Autoimmune disease1Autoimmune disease treatments1Drug safety1Neurological disorders1Randomized controlled trial1Rare diseases1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Russia-Ukraine war

136 stories

Strait of Hormuz blockage

148 stories